Genomic medicine has the potential to revolutionize clinical practice. Genetic tests can assess disease risk, inform preventive measures, predict optimal therapeutic regimens, and more.
Early detection through genetic screening can reduce the financial impact on members and health systems by lowering downstream cost of care.
In order for members to widely benefit from advances in genomics, genetic tests must be incorporated into medical health plan design.
Yuri Fesko, MD
Medical Director of Oncology
As a leading oncologist, Dr. Fesko plays a key role in helping Quest advance the field of precision medicine and give new hope to people with cancer.
Prior to joining Quest in 2017, Dr. Fesko was Director of Medical Oncology at Duke Cancer Institute in Raleigh, North Carolina, where he was responsible for the oncology service line and development of inpatient oncology, multiple network sites and infusion centers. He was also responsible for strategies including the determination of appropriate clinical trials for population and resource utilization.
Dr. Fesko received his bachelor’s degree and medical degree from Case Western Reserve University School of Medicine. He is certified by the American Board of Internal Medicine in hematology and medical oncology.
Patrick James, MD
Chief Clinical Officer, Health Plans and Policy
Dr. James earned his medical degree with honors from St. Louis University. He completed his internship and residency training in anatomic and clinical pathology with board certification at the National Naval Medical Center and post-graduate training in cytopathology with board certification at Johns Hopkins Hospital. Dr. James has served in leadership positions at Quest Diagnostics and other leading healthcare organizations, as well as the U.S. Navy.
Michael Kolodziej M.D.
Vice President and Chief Innovation Officer
Dr. Kolodziej attended college and medical school at Washington University in St. Louis where he was Phi Beta Kappa and Alpha Omega Alpha. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, Dr. Kolodziej joined the faculty at the University of Oklahoma School of Medicine where he was an associate professor. He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics committee, on the executive committee from 2002-2011, and chairman from 2004-2011.
He served as Medical Director for Oncology Services for US Oncology from 2007-2011. In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology. He joined Aetna in January, 2013 as National Medical Director, Oncology Solutions. While at Aetna, he directed Aetna’s oncology delivery reform pilots and was the architect of the Aetna Oncology Medical Home program.
He was also active in Aetna’s pharmacy policy, condition analysis, and genetics subcommittees. Dr. Kolodziej joined Flatiron Health in July, 2016 as National Medical Director, Managed Care Strategy where he applied the core tech and data capabilities of Flatiron to facilitate practice transformation and success in alternative payment models. He joined ADVI in October, 2017. He is a Fellow of the American College of Physicians. He has published and spoken extensively on payment reform, personalized medicine, and practice care delivery transformation in oncology.